The Life Sciences team advised ImmuNext Inc. on its option and license agreement with Curis, Inc. (NASDAQ: CRIS). Under the agreement, Curis has an option to obtain an exclusive, worldwide license from ImmuNext to develop and commercialize anti-VISTA antibodies for the treatment of cancer, including ImmuNext's lead compound, CI-8993, a clinical-stage monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation (VISTA) signaling pathway.
ImmuNext develops compounds on the cutting edge of immunotherapy for cancer and autoimmune diseases. ImmuNext currently has a clinical stage program with VISTA, a checkpoint regulator, and pre-clinical programs focused on the development of antibodies that target novel immuno-metabolic proteins. Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer.
For more details, read the press release.